Toll-like receptor 7 agonists and skin.

N Novak, CF Yu, T Bieber, JP Allam - Drug news & perspectives, 2008 - europepmc.org
Toll-like receptor (TLR) 7 is an intracellular TLR that is expressed on membranes of
endosomes and recognizes nucleosides and nucleotides from intracellular pathogens …

Management of superficial basal cell carcinoma: focus on imiquimod

B Raasch - Clinical, Cosmetic and Investigational Dermatology, 2009 - Taylor & Francis
Superficial basal cell carcinoma comprise up to 25% of all histological sub-types. They are
more likely to occur on younger persons and females and although generally more common …

Association of programmed death‐1 gene polymorphisms with the risk of basal cell carcinoma

F Fathi, M Ebrahimi, A Eslami, H Hafezi… - International journal …, 2019 - Wiley Online Library
Environmental and genetic factors play a fundamental role in the pathogenesis of basal cell
carcinoma (BCC) defined as the most common cancer of skin. Programmed death‐1 (PD‐1) …

[HTML][HTML] Cáncer de piel no-melanoma

BP Lobos, SA Lobos - Revista Médica Clínica Las Condes, 2011 - Elsevier
El cáncer de piel no-melanoma incluye principalmente las neoplasias queratinocíticas
(carcinoma basocelular y espinocelular) y tumores de menor frecuencia tales como …

[HTML][HTML] Periungual basal cell carcinoma: A case report with review of literature

D Bandyopadhyay, S Sen - Indian Journal of Dermatology, 2011 - journals.lww.com
Basal cell carcinomas (BCCs) are considered to be uncommon around the nail plate. An
indolent lesion of this region should arouse suspicion of potential malignancy and a skin …

Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4‐week period: a case series

R Ruiz‐Villaverde, D Sanchez‐Cano… - Journal of the …, 2009 - Wiley Online Library
Basal cell carcinoma (BCC) is a malignant cutaneous neoplasm with a tendency to spread
locally and with several clinical and histological subsets. We studied 82 patients with a …

Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series

ME Murphy, DG Brodland, JA Zitelli - Dermatologic surgery, 2008 - journals.lww.com
In 2004 imiquimod (Aldara, 3M, St. Paul, MN) was approved by the US Food and Drug
Administration (FDA) for the topical treatment of superficial basal cell carcinoma (BCC) …

Upper face rejuvenation

V Ilankovan - International Journal of Oral and Maxillofacial Surgery, 2013 - Elsevier
The area of the upper face occupies about one third of the surface area of the whole face.
The anatomical landmarks involve the forehead, brow, glabella and the upper lids …

Extirpación quirúrgica de carcinoma basocelular de cuero cabelludo.

N Porras, F Norris-Squirrell - Dermatologia Revista …, 2016 - search.ebscohost.com
Se comunica el caso de una paciente de 32 años de edad, sin antecedentes mórbidos, que
fue enviada al servicio de Dermatología del Hospital de la Florida, por tener un nevo atípico …

Вартоцид (имихимод)

ВС Смирнов, ТА Кудрявцева - 2017 - elibrary.ru
Монография посвящена описанию модификатора иммунного ответа-имихимода,
выпускаемого под оригинальным названием Aldara® и его генерического аналога …